CrystalsFirst logo — Turning Insights Into Medicines

CrystalsFirst

Turning Insights Into Medicines

Founded 2018 Germany Hamburg, Germany 18 employees Non Equity Assistance Total: $756.60K AI, Biotechnology +2

General Information

Company Name CrystalsFirst
Founded Year 2018
Location Germany Hamburg, Germany +3
Employees 18
Industries AI, Biotechnology, Health Care +1
Funding Stage Non Equity Assistance
Social

Get notified when CrystalsFirst moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CrystalsFirst

CrystalsFirst is a biotechnology startup with the slogan "Turning Insights Into Medicines." Founded in 2018 and headquartered in Germany, the company is focused on revolutionizing small molecule drug discovery through its proprietary MAGNET platform. This technology integrates structural biology, generative AI, and medicinal chemistry to detect molecular magnets, identify novel molecules, and druggable binding pockets for challenging targets. By adopting a "crystal structure first" strategy and utilizing computational modeling, the platform facilitates rapid access to diverse chemical scaffolds, hit expansion, and scaffold hopping. Notably, the recent non-equity assistance investment at 01 August 2022 from VentureOut signifies external validation of CrystalsFirst's innovative approach. The synergistic combination of these elements in the MAGNET Platform accelerates the discovery process, increasing the likelihood of finding innovative and effective therapeutic compounds. Overall, CrystalsFirst stands out as an exciting player in the biotechnology, health care, and pharmaceutical industries, poised to make substantial contributions to the advancement of drug discovery and development.

Taxonomy: drug discovery, structural biology, computational modelling, generative AI, medicinal chemistry, crystal structure, target interactions, rational design, hit expansion, scaffold hopping, compound generation, therapeutic compounds, innovative technology, pharmaceutical research

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance •••••• 1 •••• •••• 01 Aug 2022
Non Equity Assistance •••••• 1
Investor
15 May 2019
Seed Round •••••• 1 •••• •••• 14 Mar 2018
Non Equity Assistance •••••• 1 •••• •••• 01 Oct 2016

CrystalsFirst Alternatives & Competitors

CrystalsFirst vs

Mine enhanced chemical space. Design superior candidates

Seed
28 employees
Biotechnology, Information Technology
CrystalsFirst vs
Deargen
Deargen Korea South

AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.

Series B
11 employees
AI, Biotechnology
CrystalsFirst vs
Ventus Therapeutics
Ventus Therapeutics United States

Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal,...

Grant
55 employees
Biotechnology, Health Care

FAQ About CrystalsFirst

Turning Insights Into Medicines
CrystalsFirst was founded in 2018.
CrystalsFirst is headquartered in Hamburg, Germany.
CrystalsFirst operates in the following industries: AI, Biotechnology, Health Care, Pharmaceutical.
CrystalsFirst has approximately 18 employees.
CrystalsFirst has completed 4 funding rounds, raising a total of $756.60K. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to CrystalsFirst include Pharmacelera, Deargen, Ventus Therapeutics, Good Chemistry Company (acquired by SandboxAQ), Domainex. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CrystalsFirst and Pharmacelera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CrystalsFirst and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy